Mirum Pharmaceuticals, Inc. (MIRM)
96.13
+0.62
(+0.65%)
USD |
NASDAQ |
Nov 20, 16:00
96.12
-0.01
(-0.01%)
After-Hours: 20:00
Mirum Pharmaceuticals Research and Development Expense (TTM) : 347.00M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 347.00M |
| June 30, 2026 | 282.06M |
| March 31, 2026 | 237.68M |
| December 31, 2025 | 185.83M |
| September 30, 2025 | 178.77M |
| June 30, 2025 | 167.43M |
| March 31, 2025 | 154.04M |
| December 31, 2024 | 140.10M |
| September 30, 2024 | 126.97M |
| June 30, 2024 | 121.47M |
| March 31, 2024 | 110.93M |
| December 31, 2023 | 102.38M |
| September 30, 2023 | 102.54M |
| June 30, 2023 | 102.61M |
| Date | Value |
|---|---|
| March 31, 2023 | 105.97M |
| December 31, 2022 | 106.50M |
| September 30, 2022 | 103.19M |
| June 30, 2022 | 107.46M |
| March 31, 2022 | 117.10M |
| December 31, 2021 | 131.09M |
| September 30, 2021 | 133.04M |
| June 30, 2021 | 118.64M |
| March 31, 2021 | 102.22M |
| December 31, 2020 | 81.52M |
| September 30, 2020 | 66.26M |
| June 30, 2020 | 62.43M |
| March 31, 2020 | 55.47M |
| December 31, 2019 | 42.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Incyte Corp. | 3.383B |
| Galectin Therapeutics, Inc. | 7.863M |
| TG Therapeutics, Inc. | 236.22M |
| Ardelyx, Inc. | 91.28M |
| Kodiak Sciences, Inc. | 208.43M |